OncoMatch/Clinical Trials/NCT05954897
Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma
Is NCT05954897 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC for hepatocellular carcinoma.
Treatment: Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC — To evaluate the efficacy and safety of lenvatinib, tislelizumab combined with RALOX regimen HAIC in advanced hepatocellular carcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: liver transplantation
Previous liver transplantation
Lab requirements
Blood counts
Hb ≥ 90 g/dL; Neu ≥ 1.5 x 10^9/L; PLT ≥ 75 x 10^9/L; APTT ≤1.5 times the upper limit of normal
Kidney function
Cre ≤1.5 x upper limit of normal
Liver function
ALB ≥2.8 g/dL; TBIL ≤2 times the upper limit of normal; AST and ALT ≤ 3 times the upper limit of normal; Child-Pugh score ≤7
Adequate organ function, defined as: Hb ≥ 90 g/dL; Neu ≥ 1.5 x 10^9/L; PLT ≥ 75 x 10^9/L; ALB ≥2.8 g/dL; TBIL ≤2 times the upper limit of normal; AST and ALT ≤ 3 times the upper limit of normal; Cre ≤1.5 x upper limit of normal; APTT≤1.5 times the upper limit of normal. Child-Pugh score ≤7.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05954897 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages